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 Summary  25 
Background Previous systematic reviews and meta analyses explaining the relationship between carbohydrate 26 
quality and health have usually examined a single marker and a limited number of clinical outcomes. We have 27 
considered the impact of carbohydrate quality as measured by intakes of dietary fibre, whole grains or pulses, 28 
and dietary glycaemic index or glycaemic load on non-communicable disease (NCD) incidence, mortality, and 29 
risk factors to more precisely quantify the predictive potential of the markers, to determine which are most 30 
useful, and to establish an evidence base for quantitative recommendations for intakes of dietary fibre. 31 
 32 
Methods Prospective studies published prior to April 2017 and randomised controlled trials published prior to 33 
February 2018, which reported on indicators of carbohydrate quality and NCD incidence, mortality and risk 34 
factors were systematically reviewed and meta analysed. Studies were identified by searches in PubMed, Ovid 35 
Medline, Embase, and the Cochrane Central Register of Controlled Trials and by hand searching of previous 36 
publications. Searches, data extraction, and bias assessment were duplicated independently. Robustness of 37 
pooled estimates from random effects models was considered with sensitivity analyses, meta regression, dose 38 
response testing, and subgroup analyses. The GRADE approach was used to assess quality of evidence. 39 
 40 
Findings 135 million person years of data from prospective studies and 58 clinical trials with a total of 4,635 41 
adult participants were included in the analyses. Observational data suggest a 15-30% decrease in all-cause and 42 
cardiovascular related mortality, and incidence of coronary heart disease, stroke, type 2 diabetes, and colorectal 43 
cancer when comparing the highest dietary fibre consumers with the lowest. Clinical trials show significantly 44 
lower body weight, systolic blood pressure and total cholesterol when comparing higher with lower intakes. 45 
Risk reduction associated with a range of critical outcomes was greatest when daily intake of dietary fibre was 46 
between 25-29 grams. Dose response curves suggested that higher intakes may confer even greater benefit with 47 
regard to protection against cardiovascular diseases, type 2 diabetes and colorectal and breast cancer. 48 
Comparable findings for wholegrain intake were observed. Smaller or no risk reductions were found with the 49 
observational data when comparing the effects of diets characterised by low rather than higher glycaemic index 50 
or load. Overall the certainty of evidence regarding the relationships between carbohydrate quality and critical 51 
outcomes was graded as moderate for dietary fibre, low to moderate for whole grains, and low to very-low for 52 
glycaemic index. Data relating to other dietary exposures was limited. 53 
 54 
Interpretation The complementary findings from prospective studies and clinical trials relating to the reduction 55 
in mortality, NCD incidence, and their risk factors associated with relatively high intakes of dietary fibre and 56 
whole grains as well as striking dose response evidence indicate that the relationships may be causal. Benefit to 57 
individuals and populations may be expected from implementation of dietary recommendations to increase 58 
dietary fibre intake and to replace refined grains with whole grains. 59 
 60 
Funding This research was supported by funding from: the Health Research Council of New Zealand; World 61 
Health Organization; Riddet Centre of Research Excellence; Healthier Lives National Science Challenge; 62 
Department of Medicine, University of Otago; and the Otago Southland Diabetes Research Trust.   63 
 Research in Context 64 
Evidence before this study 65 
Carbohydrate-containing foods consisting principally of sugars, starches and dietary fibre (non starch 66 
polysaccharide) provide the major source of energy worldwide. The role of free sugars as a determinant of 67 
adverse health outcomes has been clarified and clear guidelines relating to their restriction issued. Dietary fibre 68 
and some starches are associated with health benefits and dietary guidelines typically encourage regular 69 
consumption of vegetables, cereals, pulses and whole fruit which are rich sources of these and other health 70 
promoting nutrients. However, previous systematic reviews and meta analyses examining the relationship 71 
between starches and dietary fibre, and health outcomes have usually examined a single indicator of 72 
carbohydrate quality and a limited number of disease outcomes. Thus it has not been possible to determine the 73 
extent to which the predictive potential of these indicators applies across the spectrum of non-communicable 74 
disease (NCDs) nor which are most useful in nutrition guidelines or when recommending food choices. 75 
Quantitative recommendations relating to dietary fibre have not had a strong evidence base. 76 
 77 
Added value of this study 78 
We have undertaken systematic reviews and meta analyses of prospective studies and clinical trials that have 79 
reported on the relationship between the most widely studied indicators of carbohydrate quality (dietary fibre, 80 
whole grains or pulses, dietary glycaemic index or glycaemic load) and mortality and incidence of a wide range 81 
of NCDs and their risk factors. Parallel consideration of prospective studies and clinical trials has enabled an 82 
exploration of the extent to which changes in cardiometabolic risk factors associated with altering intake of 83 
dietary carbohydrate align with the effect of carbohydrate quality on disease risk observed in the prospective 84 
studies. Dose response curves were generated and the benefits from different amounts of total dietary fibre were 85 
calculated. The approach recommended by the GRADE Working Group has been used to assess the quality of 86 
evidence and the magnitude and importance of the observed associations which influence the confidence in 87 
nutrition recommendations. 88 
 89 
Implications of all the available evidence 90 
The complementary findings from prospective studies and clinical trials, which show that higher intakes of 91 
dietary fibre or whole grains are related to a reduction in the risk of a wide range of NCDs and their risk factors, 92 
provide convincing evidence for nutrition recommendations to replace refined grains with whole grains and 93 
increase dietary fibre to at least 25-29g per day, with additional benefits likely to accrue with greater intakes. In 94 
the light of current evidence, dietary glycaemic index or glycaemic load may be less useful as overall measures 95 
of carbohydrate quality than dietary fibre and wholegrain content.  96 
 Introduction  97 
Prior to the mid twentieth century carbohydrates were principally regarded as an energy source and nutrition 98 
recommendations suggested that carbohydrates should contribute the energy deficit remaining after intakes of 99 
fat and protein had been specified. From the mid 1950s there was increasing awareness of the potential of 100 
“sugar” (principally sucrose) to increase the risk of dental caries and in the 1960s Yudkin1 popularised the view 101 
that sugar was a major contributing cause of obesity, type 2 diabetes and cardiovascular disease, an opinion 102 
shared by Cleave and Campbell who described these and other chronic conditions as saccharine diseases.2 A 103 
substantial body of experimental, epidemiological and clinical trial data has accumulated since these early 104 
observations and based on extensive systematic reviews and meta analyses, the World Health Organization 105 
(WHO) has recently issued a strong recommendation, based on the association between free sugars and dental 106 
caries and obesity, for individuals to reduce intake to less than 10% total energy and a conditional 107 
recommendation suggesting that even greater benefit may accrue if intakes are below 5%.3 Comparable 108 
recommendations have been made by national governments and professional organisations worldwide.  109 
 110 
It is more than half a century since Burkitt, Trowell and Painter, based largely on epidemiological observations 111 
in Africa, suggested that processing of cereal based foods (grains) with removal of what came to be called 112 
dietary fibre, rather than excessive intakes of sugar, were key determinants of both cardiometabolic and large 113 
bowel diseases.4,5 Nevertheless, until relatively recently rather less attention has been given to starches and 114 
dietary fibre, the other major components of dietary carbohydrate. While nutrition guidelines issued by many 115 
governments and professional organisations encourage increased consumption of vegetables, fruit and whole 116 
grains, there are fewer quantitative guidelines for sources and intakes of dietary fibre and starch. We report here 117 
on a series of systematic reviews and meta analyses on indicators of carbohydrate quality and non-118 
communicable disease (NCD) incidence, mortality, and risk factors. The research was commissioned by WHO 119 
to inform the development of updated recommendations regarding carbohydrate intake. 120 
 121 
Methods 122 
We followed reporting standards for systematic reviews and meta analyses.6 Literature searches, identification 123 
of eligible studies, data extraction and bias assessment were undertaken independently by at least two 124 
researchers, with discrepancies resolved with an additional reviewer.  125 
 126 
PICO tables and eligibility criteria 127 
PICO tables (Appendix A) were agreed by the WHO Nutrition Guidance Expert Advisory Group (NUGAG). 128 
We report here on markers of carbohydrate quality that have been measured in an appreciable number of studies 129 
and trials (dietary fibre, dietary glycaemic index or glycaemic load, and wholegrain intake) and outcomes 130 
specified in the PICO tables. For prospective studies critical outcomes included all-cause, coronary heart disease 131 
(CHD) and stroke mortality and incidence of CHD, stroke, type 2 diabetes, and colorectal cancer. Important 132 
outcomes included cardiovascular disease (CVD) incidence and mortality and incidence of adiposity-related 133 
cancers (breast, endometrial, oesophageal, and prostate). Prospective studies which included only cohorts with 134 
specified pre-existing conditions were excluded. 135 
 136 
 For clinical trials we have reported on adiposity, fasting glucose, fasting insulin, insulin sensitivity, HbA1c, 137 
triglycerides, cholesterol, and blood pressure. We included parallel and crossover randomised clinical trials of at 138 
least four weeks duration that reported on higher compared with lower intakes of the dietary markers. Eligible 139 
trials could include diets with test foods provided, dietary advice, ad libitum diets or controlled feeding trials on 140 
free living individuals. Weight loss trials and trials involving provision of dietary fibre supplements in the forms 141 
of powders were excluded. Comparison diets were required to be matched for macronutrient composition and 142 
lifestyle modifications such as exercise. 143 
 144 
Participants of eligible trials were adults and children free from acute or chronic disease but could include those 145 
with prediabetes, mild-moderate hypercholesterolemia, mild-moderate hypertension or metabolic syndrome. 146 
Trials including people on medications known to effect outcomes of interest or who were pregnant or in 147 
situations where regular eating habits were likely to change e.g. those suffering from eating disorders or who 148 
were breast feeding were excluded. 149 
 150 
Literature search 151 
Prospective observational studies were initially identified from systematic reviews and meta analyses that 152 
reported associations between carbohydrate intake or one of the specified measures of carbohydrate quality, and 153 
one or more of the key outcome measures. These systematic reviews were found through online searches using 154 
Ovid Medline, Embase, PubMed, Web of Science, and Scopus. This strategy was augmented by searches with 155 
low-risk-of-bias search terms for individual prospective studies and run up to the end of April 2017 to ensure 156 
identification of relevant published studies. No date or language restrictions were applied. A validation of the 157 
search procedure is provided in Appendix A. 158 
 159 
For clinical trials, highly sensitive Cochrane search strategies were used to identify trials examining the effects 160 
of carbohydrate intakes on obesity, blood pressure, and cardiometabolic risk factors. OVID Medline, Embase, 161 
Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews 162 
(CDSR), and Food Science and Technology Abstracts (FSTA) databases were searched for trials published up 163 
to February 2018. Hand searching of references of systematic reviews, prospective studies, and clinical trials 164 
were completed to identify any studies that may have been missed. Search strategies are shown in Appendix A. 165 
 166 
Study selection 167 
Reviewers identified eligible studies by screening titles, abstracts and where appropriate full texts of articles. 168 
Where there were multiple publications from the same cohort, we used data for the longest follow-up period.  169 
 170 
Data extraction 171 
Data were extracted using pre-tested forms.7 For prospective studies the most adjusted values for effect size 172 
were extracted, where that value did not also specifically include adjustment for other carbohydrates. For 173 
clinical trials involving multiple interventions we extracted data from all relevant interventions. For crossover 174 
trials involving multiple interventions we extracted data only from the most relevant intervention and either the 175 
control group or the most relevant comparator intervention. 176 
  177 
Risk of bias assessment 178 
We used the ROBIS assessment tool8 to assess systematic reviews and meta analyses for quality and risk of 179 
bias, and the Newcastle Ottawa Scale (NOS)9 to assess risk of bias of each prospective study. For clinical trials 180 
we used Cochrane criteria.10 181 
 182 
Data analysis  183 
For prospective studies we pooled the reported odds ratios or risk ratios with the DerSimonian and Laird 184 
random effects model11 in a high quantile versus low quantile analysis. When individual studies reported results 185 
separately by sex, we first combined these effect size estimates with a fixed effects model before including them 186 
within the pooled estimate. When eligible studies were based on and reported combined results from multiple 187 
cohort studies we extracted results for each cohort to include in the meta-analysis. Prospective studies reporting 188 
incidence or mortality were analysed separately. Where data were reported in a suitable format, we considered 189 
dose response relationships with the Greenland and Longnecker method12 assuming linearity with a two-stage 190 
dose response random-effects analysis. The average or mid-point of each defined quantile was used for the dose 191 
amount. Where the quantile dose range was open-ended, half the range of the adjacent quantile was used to 192 
determine the average intake. We used 30g to represent one serve of whole grains when a value for weight was 193 
not stated.13 Non-linear dose-response was assessed using restricted cubic splines with three knots at 10%, 50%, 194 
and 90% of distribution combined with multivariate meta analyses.14 We imputed the number of cases per 195 
quantile from the RR value when necessary. Linear and spline (with 95%CI) models are shown with each data 196 
point overlaid as circles. Circle size indicates the weighting of each data point with bigger circles indicating 197 
greater influence. Absolute risk values were calculated with GRADE Pro software.15 198 
 199 
To help establish optimal intakes of dietary fibre we considered the dose-response curves for total dietary fibre 200 
intake and critical health outcomes. We also compared the lowest consumers of dietary fibre with those 201 
consuming between 15-19, 20-24, 25-29, 30-34, and 35-39 grams of fibre per day with a random effects model. 202 
When studies reported more than one quantile of data within the pre-specified intake ranges, we first combined 203 
these quantiles with a fixed effects model before including them within the pooled estimate. We did this to 204 
measure the number of critical outcomes where an improvement in relative risk was observed in the higher 205 
intake categories.  206 
 207 
For clinical trials high-versus-low analyses were undertaken with generic inverse models and random-effects. 208 
For outcomes that could be measured by different units, reported effects were presented as standardised mean 209 
differences. For studies reporting multiple follow-ups over time, the most recent, appropriately reported 210 
published data were used in the meta analyses. When crossover (paired data) studies did not report the mean 211 
difference between treatments and its standard error or other relevant statistics, end of treatment values were 212 
analysed as independent samples. Subgroup analyses by fibre amount or principal starch source were conducted 213 
when there were enough studies for subgroupings including more than one trial. For example high fibre 214 
interventions (0-25, 25-30, 30-35, >35 g/day) were considered to determine whether there were threshold effects 215 
or a possible dose response.  216 
  217 
For all analyses heterogeneity was assessed with the I2 statistic,16 and the Cochrane Q test.17 Sensitivity analyses 218 
were conducted when a I2 statistic was found to be more than 50% or a p for heterogeneity of <0·10. Publication 219 
bias was assessed with Egger’s and Begg’s tests,18 and the trim and fill method.19 The effect of each individual 220 
study’s findings was considered with an influence analysis. For prospective studies analyses excluding those 221 
that scored less than six out of a possible nine with the NOS were conducted. If there was still unexplained 222 
heterogeneity we considered the impact of small studies reporting less than 200 cases or less than 2000 223 
participants. For clinical trials, analyses excluding trials with a high risk of bias for at least one criterion were 224 
conducted to examine the influence of potential bias on outcomes. Meta regression analyses further examined 225 
effects of potential explanatory factors including trial design (crossover or parallel), study or trial duration, 226 
global region, differences in fibre intake achieved, source of fibre or starch and nutrition status of participants. 227 
Analyses were performed using the Cochrane Collaboration software and Stata statistical software.20,21 228 
 229 
We used GRADE22 protocols, to judge the quality of the body of evidence as either high, moderate, low, or 230 
very-low. More detail on this approach is provided in Appendix A. Quality of the evidence was assessed by the 231 
research team and revised if required after discussion with the NUGAG Subgroup on Diet and Health.  232 
 233 
Role of the funding source 234 
With the exception of WHO, the funders of the study had no role in study design, data collection, data analysis, 235 
data interpretation, or writing the report. The corresponding author had full access to all the data in the study 236 
and had final responsibility for the decision to submit for publication. 237 
 238 
Results  239 
Data from 185 publications of prospective studies involving just under 135 million person years and 58 clinical 240 
trials with a total of 4,635 adult participants were included in the meta analyses. A flow chart of identified 241 
studies is shown in Figure 1, with details of these studies in Supplement 10. Critical outcome data for total fibre, 242 
wholegrain intake, and dietary glycaemic index are summarised in Tables 1-3 and shown in full in Appendices 243 
B-D for observational studies and Supplements 1 and 2 for trials. Dose response data are shown in Figures 2-4 244 
and the supplementary material. Summary forest plots from clinical trial data are shown in Figure 5. Data and 245 
GRADE tables relating to all other indicators and outcomes are in Supplement 1-9. 246 
 247 
Dietary fibre 248 
The observational data in Table 1 show that higher intakes of total dietary fibre are associated with a 15-31% 249 
reduction in the risk of specified critical outcomes. For all-cause mortality and coronary heart disease incidence 250 
this translates into 13 fewer deaths (95%CI 8 to 18) and 6 fewer cases of CHD (95%CI 4 to 7) per 1000 251 
participants over the duration of the studies. Sensitivity analyses of the tested associations did not change the 252 
direction or significance of any observed result. The quality of evidence contributing to the meta analyses of the 253 
cohort studies was, with the exception of the data relating to stroke, considered to be moderate. 254 
 255 
 Figure 2 shows dose response relationships for total fibre intake and total mortality, incidence of coronary heart 256 
disease, type 2 diabetes and colorectal cancer, many of which are linear with no sign of a plateau within the 257 
available data. When comparing the lowest fibre intakes with pre-specified ranges the greatest benefits were 258 
observed for those consuming 25-29g per day (improvement in 6 of the 7 critical outcomes), more so than those 259 
consuming between 15-19g per day (improvement in 3 of the 7 critical outcomes), or 20-24g per day 260 
(improvement in 4 of the 7 critical outcomes). These analyses are shown in full in Appendix B. 261 
 262 
Mean differences between higher versus lower fibre intakes for a range of cardiometabolic risk factors are 263 
shown in Table 1 and the summary forest plots in Figure 5a. Dose response or threshold effects could not be 264 
determined from the clinical trial data. The quality of evidence contributing to the meta analyses of the trial data 265 
relating to body weight is high and total cholesterol and systolic blood pressure moderate because of 266 
unexplained heterogeneity between the trials. 267 
 268 
Broadly similar effects were apparent in both the prospective studies and clinical trials, when examining fibre 269 
from different food groups or fibre described as soluble or insoluble, though limited data were available, other 270 
than for cereal fibre, the largest contributor to total dietary fibre (Supplements 1-9). 271 
 272 
Whole grains 273 
Cohort data showing the relationship between whole grains and the effect of increasing wholegrain intake on 274 
critical outcomes are shown in Table 2. Higher intakes of whole grains were associated with a 13-33% reduction 275 
in the risk. For all-cause mortality and coronary heart disease incidence this translates into 26 fewer deaths 276 
(95%CI 14 to 39) and 7 fewer cases (95%CI 3 to 10) per 1000 participants over the duration of the studies. 277 
Sensitivity analyses did not typically change the direction or significance of any pooled effect. The quality of 278 
evidence relating to colorectal cancer incidence is moderate, whilst for other critical outcomes it is low due to 279 
high heterogeneity not fully explained by sensitivity analysis. Dose response curves showing clear associations 280 
with increasing wholegrain intake and all-cause mortality or risk of coronary heart disease, type 2 diabetes, and 281 
colorectal cancer incidence are shown in Figure 3. Mean differences in cardiometabolic risk factors between 282 
higher and lower wholegrain consumption are shown in Table 2 and summary forest plots in Figure 5b. 283 
Evidence relating to body weight, cholesterol, and blood pressure is graded as moderate, downgraded due to 284 
unexplained heterogeneity. 285 
 286 
Glycaemic index 287 
Cohort data showing the relationship between dietary glycaemic index and the effect of decreasing the dietary 288 
glycaemic index on critical outcomes as demonstrated in the trials are shown in Table 3, dose responses are 289 
shown in Figure 4, and summary forest plot in Figure 5c. Data relating to the cohort studies which examined the 290 
effects of glycaemic load are presented in Supplement 3.  291 
 292 
An 11% (95%CI 3% to 18%) relative risk reduction of type 2 diabetes was observed for those consuming low 293 
glycaemic index diets. However sensitivity analysis due to high heterogeneity attenuated the relative risk 294 
reduction to 5% (95%CI 13% less to 4% more). Stroke mortality was lower amongst those consuming lower 295 
 glycaemic index diets. The prospective studies generated evidence that is graded as low or very-low quality as a 296 
result of high risk of bias, imprecision, and inconsistencies. Key outcome markers from the clinical trials on 297 
decreasing the glycaemic index of a diet are shown in forest plots in Figure 5c. Trial data were usually of 298 
moderate quality. 299 
 300 
Discussion  301 
Higher intakes of total dietary fibre or whole grains result in reduced incidence and mortality from several 302 
NCDs. Less useful markers of carbohydrate quality are glycaemic index, glycaemic load, and sources of dietary 303 
fibre where inconsistent findings or insufficient data provide low or very low quality evidence. In randomised 304 
trials higher intakes of dietary fibre reduce body weight, lower blood cholesterol and systolic blood pressure. 305 
These findings are supported by cohort studies that report reduced risk of coronary heart disease incidence and 306 
mortality and diabetes incidence. The consistency between the trial and prospective study results together with 307 
the dose response relationships are evidence that the effect on cardiometabolic diseases are likely to be causal 308 
and not a consequence of confounding. In addition, prospective studies show striking reductions in and dose 309 
response relationships with all-cause mortality, total cancer deaths, total cardiovascular disease, stroke 310 
incidence, and colorectal, breast, and oesophageal cancer. For several of these outcomes the dose response is 311 
linear. These findings together with the comparisons of clinical outcomes amongst those with different intakes 312 
of dietary fibre suggest that individual adult intakes of total dietary fibre should be no less than 25 to 29 grams 313 
per day with additional benefits likely to accrue with higher intakes. Population intakes in this range are 314 
reported in some countries, but the majority consume less than 20 grams a day.23 Broadly similar trends were 315 
apparent in the prospective studies that examined cereal fibre, typically the largest contributor to total dietary 316 
fibre. Limited data were available regarding specific sources (legume, fruit, vegetable) or subcategories 317 
(‘soluble’, ‘insoluble’, or extracted) of dietary fibre. 318 
 319 
The results for wholegrain foods reflect those for dietary fibre. Prospective studies showed a reduction in all-320 
cause mortality, coronary heart disease, cancer deaths, and incidence of type 2 diabetes. As with dietary fibre 321 
the observed reductions in risk are considerable, typically around 20% with significant dose response 322 
relationships. The randomised controlled trials involving an increase in the amount of whole grains showed 323 
improvements in body weight and lipids. The similar protective effects of higher intakes of wholegrain foods 324 
and of dietary fibre suggest that the beneficial effects of whole grains may be due to their typically high dietary 325 
fibre content. The GRADE criteria categorise the evidence linking most clinical outcomes with dietary fibre as 326 
moderate, and with whole grains as low quality. 327 
 328 
Dietary starch can be divided into several categories24 although rarely are measurements made of these 329 
individual components in either prospective studies or randomised controlled trials. However the glycaemic 330 
index of starch-containing foods or the overall glycaemic load of meals or diets including starchy foods provide 331 
measures of starch quality and are widely reported. We have found that diets with a lower overall glycaemic 332 
index appear to be associated with a reduced risk of stroke and type 2 diabetes. However the risk estimates, 333 
other than for stroke mortality, are modest when compared with those for dietary fibre and following sensitivity 334 
analyses were reduced and associated with confidence intervals which included 1. The findings from 335 
 prospective studies of glycaemic load are inconsistent. The results from trials show no consistent benefits on the 336 
clinical outcomes when changing the glycaemic index of a diet.  337 
 338 
A major strength of the present study is that it has related key markers of carbohydrate quality to total mortality 339 
and mortality and incidence of the major nutrition-related non-communicable diseases and that prospective 340 
studies have been considered alongside randomised controlled trials. Other reviews and meta analyses have 341 
reported on a single indicator of carbohydrate quality and one or more outcomes. Our approach has enabled us 342 
to use these indicators of carbohydrate quality to provide a stronger justification than had previously been 343 
available for a quantitative recommendation relating to dietary fibre intake. That the evidence for the 344 
associations between the quality markers and outcomes was most frequently rated as ‘moderate’ or ‘low’ rather 345 
than ‘high’ may be regarded as a limitation. However this is an inevitable consequence of the use of GRADE 346 
criteria for assessment which typically require evidence from randomised controlled trials with disease 347 
endpoints in order to be rated as being of ‘high’. Furthermore when using the GRADE approach downgrading 348 
frequently occurs as a consequence of unexplained heterogeneity amongst the results of the different studies, 349 
even when all trend in a similar direction. This may be a consequence of studies being carried out in diverse 350 
populations or as a result of different methods of measuring dietary intake. With regard to the associations we 351 
have reported here between dietary fibre and whole grains and a wide range of clinical outcomes, the 352 
consistency of the findings, the striking dose response relationships and the substantial body of mechanistic 353 
evidence all contribute to the totality of evidence and increases our confidence in the findings. 354 
 355 
Our findings are broadly comparable with other reviews and meta analyses that have reported on the association 356 
between dietary fibre and whole grains and one or more disease outcomes.25-28 However there is less consistency 357 
in our findings than in earlier reports with regard to the potential benefit of low glycaemic index or glycaemic 358 
load diets. Three systematic reviews have shown a reduced incidence of type 2 diabetes associated with the 359 
consumption of diets of lower glycaemic index or glycaemic load,29-31 though the effect was modest when 360 
compared with the protective effect of total dietary fibre or wholegrains. In the present study sensitivity analyses 361 
due to high heterogeneity reduced risk reduction and confidence intervals included 1. A review of prospective 362 
studies by Turati et al.32 suggested a small but significant increase in colorectal cancer incidence associated with 363 
high glycaemic index or glycaemic load. This finding was subject to high unexplained heterogeneity and 364 
included retrospective case-control studies which may be subject to dietary recall bias. Other studies have 365 
reported a lower incidence of stroke and CHD amongst those consuming low glycaemic index or glycaemic load 366 
diets,29,33-36 whilst we found a reduced risk of stroke only. We were unable to confirm an effect of low 367 
glycaemic index or glycaemic load diets on haemoglobin A1c or blood cholesterol which have been reported in 368 
many short and medium term trials. However we excluded trials which involved only people with diabetes or 369 
marked hyperlipidaemia who were the participants in the majority of trials reporting reduction in these 370 
important risk indicators. Our study does not exclude the value of these indicators of carbohydrate quality in this 371 
clinical context.  372 
 373 
Whole grains offer a useful means of increasing dietary fibre intake and reducing risk of NCDs. However fruit 374 
and vegetables are also important contributors to dietary fibre intake. We did not specifically explore the 375 
 relationship between fruit and vegetable consumption and NCDs given the recent systematic review and meta 376 
analyses by Aune et al.37 They report risk reductions of around 10% per 200g fruit and vegetables combined for 377 
CHD, stroke and total mortality and smaller but still significant reductions for total cardiovascular disease and 378 
cancer. Appreciable dose response effects were apparent for most outcomes up to 800g/day. Inverse associations 379 
were observed between the intake of apples, pears, citrus fruits, green leafy vegetables, cruciferous vegetables 380 
and salad and cardiovascular disease and all-cause mortality. Intake of green yellow vegetables and cruciferous 381 
vegetables were inversely associated with total cancer risk In addition to fibre, fruits and vegetables contain 382 
many other nutrients that are potentially protective and confer some risk reduction. 383 
 384 
The benefits of fibre reported in the present and other papers are supported by over 100 years of research into its 385 
chemistry, physical properties, physiology and metabolic effects.23,38-40 Fibre containing foods must be chewed 386 
before passing through the stomach and into small bowel where they affect satiety, glucose and insulin 387 
responses and lipid absorption. Whilst more recent systematic reviews have shown only small effects on 388 
appetite, satiety or blood lipids41,42 these studies have been conducted largely using defined fibre supplements 389 
rather than whole foods. Whole foods that require chewing and retain much of their structure in the gut are more 390 
likely to increase satiety through a variety of mechanisms leading to weight loss and to modulation of 391 
carbohydrate and lipid metabolism. In the large bowel fibre is almost completely broken down by the resident 392 
microflora in a series of anaerobic reactions known as fermentation.43 The gut microbiota play a number of 393 
important roles in human health including protecting against pathogens, development of the gut immune system, 394 
vitamin synthesis, metabolism of xenobiotics and may be involved in complex gut-brain communication. 395 
However the principal function of the microbiome is digestion of fibre and other carbohydrates that escape 396 
breakdown in the small bowel and it is the availability of fibre in the diet that dominates the metabolism of the 397 
gut microbiome and leads to protection from conditions such as colorectal cancer.44,45 This coming together of 398 
the epidemiological and experimental work on fibre allows conclusions to be drawn that increased fibre intakes 399 
should result in improvements in population health.  400 
 401 
While we have not considered the evidence regarding total carbohydrate intake, epidemiological evidence and 402 
relatively long term clinical trials46 suggest that a wide range of intakes is acceptable, a finding which is 403 
endorsed by authoritative dietary guidelines.47  Our study contributes to the growing body of evidence that 404 
carbohydrate quality rather than quantity determines major health outcomes. Translating these findings 405 
regarding dietary fibre and whole grains into dietary advice for individuals and populations should be 406 
accompanied by a caveat. Dietary fibre as defined by Codex Alimentarius is naturally occurring in foods, but 407 
may be extracted from foods or synthesised and added into manufactured foods. The large body of literature 408 
which contributed to this and other systematic reviews and meta analyses relate principally to fibre rich foods 409 
since most of the studies were undertaken before synthetic and extracted fibre were widely used. The concept of 410 
wholegrain foods has also changed appreciably. Wholegrain foods are required to have a nutrient composition 411 
similar to that of the original grain, without regard to the degree of processing. Many breakfast cereals and other 412 
manufactured “whole grain” products are more highly processed than in the past. There is limited, but quite 413 
striking evidence that increased processing of whole grains can result in a deterioration of a several biomarkers 414 
of cardiometabolic disease.48 As these are relatively recent developments there is no epidemiological evidence 415 
 of the consequences of these changes in the food supply on clinical outcomes and mortality. Until such evidence 416 
is available it seems appropriate that dietary advice should emphasise the benefits of naturally occurring dietary 417 
fibre in whole grains, vegetables and fruits that have been minimally processed. 418 
 419 
There is a considerable body of evidence relating to the adverse consequences of high intakes of sugar 420 
sweetened beverages and strong recommendations to reduce the intake of free sugars.3 Our findings based on a 421 
series of systematic reviews and meta analyses provide strong evidence for the importance of including advice 422 
regarding the nature and source of other carbohydrates in dietary guidelines aimed at reducing the risk of NCDs. 423 
Diets high in total dietary fibre especially from whole grains and, on the basis of another recent systematic 424 
review,36 vegetables and fruits, are associated with a significant reduction in a range of NCDs when compared 425 
with lower dietary fibre and refined rather than whole grain intakes. The types of studies we have considered did 426 
not identify risks associated with dietary fibre. However high intakes may be associated with deleterious effects 427 
in populations with borderline iron/mineral status, amongst whom very high whole grain intakes may further 428 
compromise iron status.49 High intakes of dietary fibre and whole grains are more clearly associated with good 429 
health outcomes than measures of glycaemic index or glycaemic load. Whilst glycaemic index provides a 430 
measure of the glycaemic potential of the carbohydrate content of foods, some low glycaemic index foods may 431 
have other attributes, which are not health promoting. Foods containing added fructose or sucrose and 432 
composite foods containing both saturated fat and carbohydrate (e.g. confectionary products) may have a low 433 
glycaemic index.50 Our complementary findings from randomised controlled trials and prospective studies 434 
together with the dose response effects, supported by much experimental work, are evidence that diets 435 
characterised by a low content of dietary fibre contribute to the cause of a number of NCDs and that benefit will 436 
accrue from implementation of quantitative recommendations regarding dietary fibre intake. Intakes in the range 437 
of 25 to 29g daily are optimal whilst the dose response data show that amounts greater than 30g per day confer 438 
additional benefits. 439 
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 Figure 1 Flow chart indicating the process by which eligible prospective studies and randomised 571 
controlled trials were identified572 
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 574 




Type of study 
Number of cases or 
N in intervention 
Person years or 
N of controls 
Effect size (95%CI) 
GRADE 
quality  
All-cause mortality 10 observational 80,139 12·3 million PY RR 0·85 (0·79 to 0·91) Moderate 
CHD mortality 10 observational  7,243 6·9 million PY RR 0·69 (0·60 to 0·81)* Moderate 
CHD incidence 9 observational  7,155 2·7 million PY RR 0·76 (0·69 to 0·83) Moderate 
Stroke mortality 2 observational  1,103 1·3 million PY RR 0·80 (0·56 to 1·14) Very low  
Stroke incidence 9 observational  13,134 4·6 million PY RR 0·78 (0·69 to 0·88)** Low 
Cancer mortality 5 observational  29,593 11·2 million PY RR 0·87 (0·79 to 0·95) Moderate 
Type 2 diabetes incidence 17  observational  48,468 6·9 million PY RR 0·84 (0·78 to 0·90) Moderate 
Colorectal cancer incidence 22 observational  22,920 16·9 million PY RR 0·84 (0·78 to 0·89) Moderate  
Change in body weight (kg) 27 randomised trials 1,294 1201 
MD 0·37 lower  
(0·63 kg lower to 0·11 kg lower) 
High 
Change in HbA1c (%) 6 randomised trials 191 189 
SMD 0·35 lower  
(0·73 lower to 0·03 higher) 
Low 
Change in total cholesterol (mmol/L) 36 randomised trials 1,832 1,671 
MD 0·15 lower**  
(0·22 lower to 0·07 lower) 
Moderate 
Change in systolic blood pressure 
(mm Hg) 
15 randomised trials 1,064 988 
MD 1·27 lower**  
(2·50 lower to 0·04 lower) 
Moderate 
PY person years, RR relative risk, MD mean difference, SMD standardised mean difference  576 
* Egger’s test for bias p = 0·0040. Trim and fill analysis did not change the direction or significance of the pooled estimate. 577 
** The high heterogeneity of the pooled effect size (>50%) is unexplained by sensitivity analyses.  578 
 579 
Detailed justification for the GRADE quality of evidence is given in Appendix B for observational studies and Supplement 1 for trials.  580 




Type of study 
Number of 
cases or N in 
intervention 
Person years or 
N of controls 
Effect size (95%CI) GRADE quality  
All-cause mortality 9 observational 99,224 10·7 million PY  RR 0·81 (0·72 to 0·90)* Low 
CHD mortality 2 observational  1,588 2·0 million PY RR 0·66 (0·56 to 0·77) Low 
CHD incidence 6 observational  7,697 2·8 million PY RR 0·80 (0·70 to 0·91)* Low 
Stroke mortality 2 observational  694 2·0 million PY RR 0·74 (0·58 to 0·94) Low  
Stroke incidence 3 observational  1,247 1·1 million PY RR 0·86 (0·61 to 1·21) Very low 
Cancer mortality 5 observational  32,727 10·1 million PY RR 0·84 (0·76 to 0·92)* Low 
Type 2 diabetes incidence 8 observational  14,686 3·9 million PY RR 0·67 (0·58 to 0·78)* Low 
Colorectal cancer incidence 7 observational  8,803 6·8 million PY  RR 0·87 (0·79 to 0·96) Moderate 
Change in body weight (kg) 11 randomised trials 498 421 
MD 0·62 lower  
(1·19 lower to 0·05 lower) 
Moderate 
Change in HbA1c (%) 3 randomised trials 141 141 
SMD 0·54 lower  
(1·28 lower to 0·20 higher) 
Low 
Change in total cholesterol 
(mmol/L) 
17 randomised trials 772 701 
MD 0·09 lower  
(0·23 lower to 0·04 higher) 
Moderate 
Change in systolic blood pressure 
(mm Hg) 
8 randomised trials 493 432 
MD 1·01 lower  
(2·46 lower to 0·44 higher) 
Moderate 
PY person years, RR relative risk, MD mean difference, SMD standardised mean difference  582 
* The high heterogeneity of the pooled effect size (>50%) is unexplained by sensitivity analyses.  583 
 584 
 585 
Detailed justification for the GRADE quality of evidence is given in Appendix C for observational studies and Supplement 2 for trials. 586 
  587 




Type of study 
Number of cases or 
N in intervention 
Person years or 
N of control 
Effect size (95%CI) GRADE quality  
All-cause mortality 3 observational 7,698 0·6 million PY RR 0·89 (0·70 to 1·13)* Very low 
CHD mortality 1 observational incidence not stated 0·04 million PY RR 1·10 (0·69 to 1·75) Very low 
CHD incidence 10 observational  
8,456 + not reported 
in one study  
2·4 million PY  RR 0·93 (0·83 to 1·04) Low 
Stroke mortality 3 observational  951 1·2 million PY RR 0·63 (0·52 to 0·77) Low 
Stroke incidence** 5 observational  5,527 3·0 million PY RR 0·84 (0·72 to 0·99) Very low 
Cancer mortality 1 observational 1,401 0·4 million PY RR 1·11 (0·90 to 1·38) Very low 
Type 2 diabetes incidence** 14 observational  36,908 6·5 million PY  RR 0·89 (0·82 to 0·97)* Very low 
Colorectal cancer incidence 10 observational  11,245 8·8 million PY RR 0·91 (0·82 to 1·01)* Very low 
Change in body weight (kg) 8 randomised trials 464 335 
MD 0·29 lower  
(0·62 lower to 0·03 higher) 
High 
Change in HbA1c (%) 2 randomised trials 44 37 
SMD 0·08 higher  
(0·35 lower to 0·52 higher) 
Very low 
Change in total cholesterol (mmol) 8 randomised trials 605 478 
MD 0·02 lower  
(0·17 lower to 0·13 higher) 
Moderate 
Change in systolic blood pressure 
(mm Hg) 
4 randomised trials 519 397 
MD 0·17 lower 
(1·03 lower to 0·69 higher) 
High 
PY person years, RR relative risk, MD mean difference, SMD standardised mean difference  589 
* The high heterogeneity of the pooled effect size (>50%) is unexplained by sensitivity analyses.  590 
** The pooled effect size did not maintain statistical significance during sensitivity analyses. 591 
*** Only one eligible trial of children was identified in our systematic searches. Although the exposure was for diets of higher and lower GI, data from this trial has not been 592 
included with that of adults shown above. 593 
 594 
 595 
Detailed justification for the GRADE quality of evidence is given in Appendix D for observational studies and Supplement 2 for trials. 596 
 597 
 Figure 2 Dose response relationships between total dietary fibre and critical clinical outcomes based on data 
from prospective studies.  
Fig 2a Total fibre and all-cause mortality. 68,183 deaths 
over 11·3 million person years. Assuming linearity a 
reduced risk ratio of 0·93 (0·90 to 0·95) was observed for 






Fig 2b Total fibre and coronary heart disease incidence. 
6,449 deaths over 2·5 million person years. Assuming 
linearity a reduced risk ratio of 0·81 (0·73 to 0·90) was 






Fig 2c Total fibre and incidence of type 2 diabetes. 
22,450 cases over 3·2 million person years. 
Assuming linearity a reduced risk ratio of 0·85 (0·82 to 
0·89) was observed for every 8 grams more fibre 






Fig 2d Total fibre and incidence of colorectal cancer. 
20,009 cases over 20·9 million person years. Assuming 
linearity a reduced risk ratio of 0·92 (0·89 to 0·95) was 
observed for every 8 grams more fibre consumed per day. 
 
  
 Figure 3 Dose response relationships between wholegrain intake and critical clinical outcomes based on data 
from prospective studies.  
Fig 3a Wholegrain intake and all-cause mortality. 88,347 
deaths over 8·2 million person years. Assuming linearity a 
reduced risk ratio of 0·94 (0·92 to 0·95) was observed for 






Fig 3b Wholegrain intake and incidence of coronary heart 
disease. 6,587 cases over 2·4 million person years. 
Assuming linearity a reduced risk ratio of 0·93 (0·89 to 
0·98) was observed for every 15 grams more whole grains 





Fig 3c Wholegrain intake and incidence of type 2 diabetes. 
13,147 cases over 3·5 million person years. 
Assuming linearity a reduced risk ratio of 0·88 (0·81 to 
0·95) was observed for every 15 grams more whole 





Fig 3d Wholegrain intake and incidence of colorectal 
cancer. 6,056 cases over 5·7 million person years. Assuming 
linearity a reduced risk ratio of 0·97 (0·95 to 0·99) was 
observed for every 15 grams more whole grains consumed 
per day.  
 Figure 4 Dose response relationships between dietary glycaemic index and critical clinical outcomes based on 
data from prospective studies.  
 Fig 4a Glycaemic index and all-cause mortality. 7,699 
deaths over 0·6 million person years. Assuming linearity a 
risk ratio of 1·16 (0·90 to 1·49) was observed for every 10 






Fig 4b Glycaemic index and coronary heart disease 
incidence. 7,240 cases over 2·4 million person years. 
Assuming linearity a risk ratio of 1·09 (0·94 to 1·27) 







Fig 4c Glycaemic index and incidence of type 2 diabetes. 
31,780 cases over 4·9 million person years. Assuming 
linearity a risk ratio of 1·10 (1·00 to 1·20) was observed for 






Fig 4d Glycaemic index and incidence of colorectal cancer. 
10,390 cases over 6·5 million person years. Assuming 
linearity a risk ratio of 1·05 (1·00 to 1·10) was observed for 




 Figure 5 Summary forest plots of key outcomes from clinical trials.  
Fig 5a Higher compared with lower total fibre intakes. 
 
Figure 5b Higher compared with lower wholegrain intakes. 
 
Figure 5c Comparison of diets characterised by lower compared with higher glycaemic index foods. 
 
 
 
 
